171 related articles for article (PubMed ID: 25761907)
1. Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.
Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Morandini R; Doumont G; Sherer F; Van Simaeys G; Goldman S; Ghanem G; Flamen P
Mol Imaging Biol; 2015 Oct; 17(5):697-703. PubMed ID: 25761907
[TBL] [Abstract][Full Text] [Related]
2. N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by
Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Larsimont D; Doumont G; Van Simaeys G; Goldman S; Flamen P; Ghanem G
Oncotarget; 2017 Aug; 8(34):56185-56198. PubMed ID: 28915583
[TBL] [Abstract][Full Text] [Related]
3. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
5. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
6. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
[TBL] [Abstract][Full Text] [Related]
8. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
9. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
[TBL] [Abstract][Full Text] [Related]
10.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
11. Catecholamine-Induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression.
Shi M; Yang Z; Hu M; Liu D; Hu Y; Qian L; Zhang W; Chen H; Guo L; Yu M; Song L; Ma Y; Guo N
J Immunol; 2013 Jun; 190(11):5600-8. PubMed ID: 23630346
[TBL] [Abstract][Full Text] [Related]
12. [
Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
[TBL] [Abstract][Full Text] [Related]
13. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
14. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
19. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
20. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
